Immunome宣布首例患者入组,启动评估FAP靶向放射性配体疗法IM-3050治疗FAP表达晚期实体瘤的I期临床试验

美股速递
Jul 20

Immunome公司宣布,其针对成纤维细胞活化蛋白(FAP)表达晚期实体瘤的靶向放射性配体疗法IM-3050,已在I期临床试验中完成首例患者给药。该试验旨在评估IM-3050的安全性、耐受性及初步疗效。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10